177 related articles for article (PubMed ID: 36457016)
1. Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC.
Sun Y; Yang J; Li Y; Luo J; Sun J; Li D; Wang Y; Wang K; Yang L; Wu L; Sun X
Mol Cancer; 2022 Dec; 21(1):212. PubMed ID: 36457016
[TBL] [Abstract][Full Text] [Related]
2. c-Met-Targeting
Li D; Yang J; Xu Z; Li Y; Sun Y; Wang Y; Zou H; Wang K; Yang L; Wu L; Sun X
Int J Nanomedicine; 2023; 18():2181-2196. PubMed ID: 37131548
[TBL] [Abstract][Full Text] [Related]
3. Alveolar Macrophages-Mediated Translocation of Intratracheally Delivered Perfluorocarbon Nanoparticles to Achieve Lung Cancer
Wang H; Li X; Wang J; Wang J; Zou H; Hu X; Yang L; Shen P; A R; Wang K; Li Y; Yang J; Wang K; Yang L; Wu L; Sun X
Nano Lett; 2023 Apr; 23(7):2964-2973. PubMed ID: 36947431
[TBL] [Abstract][Full Text] [Related]
4. An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration.
Yang J; Li Y; Sun J; Zou H; Sun Y; Luo J; Xie Q; A R; Wang H; Li X; Wang K; Yang L; Ma T; Wu L; Sun X
ACS Nano; 2022 Aug; 16(8):12590-12605. PubMed ID: 35863049
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Wu YL; Zhang L; Kim DW; Liu X; Lee DH; Yang JC; Ahn MJ; Vansteenkiste JF; Su WC; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan DSW
J Clin Oncol; 2018 Nov; 36(31):3101-3109. PubMed ID: 30156984
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticles for "two color"
Koshkina O; White PB; Staal AHJ; Schweins R; Swider E; Tirotta I; Tinnemans P; Fokkink R; Veltien A; van Riessen NK; van Eck ERH; Heerschap A; Metrangolo P; Baldelli Bombelli F; Srinivas M
J Colloid Interface Sci; 2020 Apr; 565():278-287. PubMed ID: 31978790
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor.
Yuan ZQ; Chen WL; You BG; Liu Y; Yang SD; Li JZ; Zhu WJ; Zhou XF; Liu C; Zhang XN
J Control Release; 2017 Dec; 268():198-211. PubMed ID: 29061511
[TBL] [Abstract][Full Text] [Related]
9. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A
Ann Oncol; 2017 Oct; 28(10):2451-2457. PubMed ID: 28961841
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib loaded polydopamine-polylactide-TPGS nanoparticles in targeted therapy for non-small cell lung cancer.
Wang H; Wu Y; Lin X
Med Oncol; 2022 Dec; 40(1):26. PubMed ID: 36459216
[TBL] [Abstract][Full Text] [Related]
11. A Theranostic Cellulose Nanocrystal-Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma.
Imlimthan S; Khng YC; Keinänen O; Zhang W; Airaksinen AJ; Kostiainen MA; Zeglis BM; Santos HA; Sarparanta M
Small; 2021 May; 17(18):e2007705. PubMed ID: 33738957
[TBL] [Abstract][Full Text] [Related]
12. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
[TBL] [Abstract][Full Text] [Related]
13. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
14. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
15. A stable, highly concentrated fluorous nanoemulsion formulation for in vivo cancer imaging via
Heaton AR; Lechuga LM; Tangsangasaksri M; Ludwig KD; Fain SB; Mecozzi S
NMR Biomed; 2024 May; 37(5):e5100. PubMed ID: 38230415
[TBL] [Abstract][Full Text] [Related]
16. Enhanced and Prolonged Antitumor Effect of Salinomycin-Loaded Gelatinase-Responsive Nanoparticles via Targeted Drug Delivery and Inhibition of Cervical Cancer Stem Cells.
Wang Q; Liu F; Wang L; Xie C; Wu P; Du S; Zhou S; Sun Z; Liu Q; Yu L; Liu B; Li R
Int J Nanomedicine; 2020; 15():1283-1295. PubMed ID: 32161458
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions.
Rapoport N; Nam KH; Gupta R; Gao Z; Mohan P; Payne A; Todd N; Liu X; Kim T; Shea J; Scaife C; Parker DL; Jeong EK; Kennedy AM
J Control Release; 2011 Jul; 153(1):4-15. PubMed ID: 21277919
[TBL] [Abstract][Full Text] [Related]
18. Development of paclitaxel loaded pegylated gelatin targeted nanoparticles for improved treatment efficacy in non-small cell lung cancer (NSCLC): an in vitro and in vivo evaluation study.
Gu M; Luan J; Song K; Qiu C; Zhang X; Zhang M
Acta Biochim Pol; 2021 Aug; 68(4):583-591. PubMed ID: 34355554
[TBL] [Abstract][Full Text] [Related]
19. Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC).
Parvathaneni V; Goyal M; Kulkarni NS; Shukla SK; Gupta V
Pharm Res; 2020 Jun; 37(7):123. PubMed ID: 32514688
[TBL] [Abstract][Full Text] [Related]
20. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
Pang J; Xing H; Sun Y; Feng S; Wang S
Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
